Tesofensine
Also known as: NS2330 · Triple Reuptake Inhibitor
A triple monoamine reuptake inhibitor that reduces appetite and increases metabolic rate by enhancing dopamine, norepinephrine, and serotonin signaling.
Overview
Tesofensine is a novel triple monoamine reuptake inhibitor that blocks the reuptake of dopamine, norepinephrine, and serotonin, originally developed for Parkinson's and Alzheimer's disease. During clinical trials for neurological conditions, researchers noticed significant weight loss in participants, leading to its repurposing as an anti-obesity drug. In Phase 2 obesity trials, tesofensine produced dose-dependent weight loss of up to 12.8% over 24 weeks — roughly twice the efficacy of existing anti-obesity medications at the time. It works through dual mechanisms: reducing appetite via enhanced serotonin and norepinephrine signaling in the hypothalamus, and increasing resting metabolic rate via sympathetic nervous system activation.
Tesofensine has been approved in some markets and continues development for obesity treatment.
Mechanism of Action
Inhibits the reuptake of dopamine (DAT), norepinephrine (NET), and serotonin (SERT) transporters. Enhanced serotonin and norepinephrine in the hypothalamus reduces appetite. Increased norepinephrine activates the sympathetic nervous system, raising metabolic rate and thermogenesis. Dopamine enhancement improves motivation and reward signaling.
Key Benefits
Potential Side Effects
Common Stacks
This peptide is commonly combined with the following compounds for synergistic effects:
Known Interactions
The following interactions have been documented for Tesofensine. Always consult a healthcare professional before combining compounds.
Use Caution (1)
Both suppress appetite through different mechanisms. Combined use may cause excessive appetite suppression, nutritional deficiencies, and cardiovascular strain.
Scientific References
Quick Reference
Typical Dose
250mcg-1000mcg
Frequency
1x daily AM
Route
Oral or injectable
Half-Life
~8-9 days
Cycle Length
4-12 weeks; 5 on 2 off or daily, followed by 4-12 weeks recovery. Fasted recommended.
FDA Status
Investigational — Phase 3 trials ongoing. Approved in some markets (Mexico). Not FDA approved in the US.
Need to calculate dosing?
Use our reconstitution calculator to determine exact syringe measurements.
Open CalculatorThis information is for educational purposes only. Consult a qualified healthcare professional before using any peptide. Dosing information reflects commonly reported protocols and may not be appropriate for everyone.
Related Peptides in Fat Loss & Metabolic
Semaglutide
An FDA-approved GLP-1 receptor agonist that has revolutionized weight management, producing average weight loss of 15-17% of body weight in clinical trials.
Read moreTirzepatide
A first-in-class dual GIP/GLP-1 receptor agonist that has demonstrated the most potent weight loss results of any pharmaceutical agent, averaging 20-26% body weight reduction.
Read moreAOD-9604
A modified fragment of human growth hormone (amino acids 176-191) that retains the fat-burning properties of HGH without its growth-promoting or diabetogenic effects.
Read more